Business Standard

Sunday, December 22, 2024 | 05:30 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Zydus Cadila receives USFDA tentative approval for Empagliflozin and Metformin Hydrochloride Tablets

Image

Capital Market
Zydus Cadila has received tentative approval from the USFDA to market Empagliflozin and Metformin Hydrochloride Tablets, 5 mg/500 mg, 5 mg/1000 mg, 12.5 mg/500 mg, and 12.5 mg/1000 mg (US RLD: SynjardyTM Tablets).

A combination of 2 drugs: empagliflozin and metformin, this medication is used with a proper diet and exercise programme to control high blood sugar in people with type 2 diabetes. It will be manufactured at the group's formulations manufacturing facility at SEZ in Ahmedabad.

The group now has 289 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

 

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 02 2020 | 11:39 AM IST

Explore News